Associations among plasma concentrations of regorafenib and its metabolites, adverse events, and ABCG2 polymorphisms in patients with metastatic colorectal cancers-Reference-Cited by-同舟云学术

Associations among plasma concentrations of regorafenib and its metabolites, adverse events, and ABCG2 polymorphisms in patients with metastatic colorectal cancers

Published:2021-02-26 Issue:6 Volume:87 Page:767-777
ISSN:0344-5704
Container-title:Cancer Chemotherapy and Pharmacology
language:en
Short-container-title:Cancer Chemother Pharmacol

Author:

Kobayashi Kazuo^ORCID,Sugiyama Erika,Shinozaki Eiji,Wakatsuki Takeru,Tajima Masataka,Kidokoro Hiyori,Aoyama Takeshi^ORCID,Nakano Yasuhiro,Kawakami Kazuyoshi^ORCID,Hashimoto Koki,Suenaga Mitsukuni,Ichimura Takashi,Ogura Mariko,Chin Keisho,Nakayama Izuma,Ooki Akira,Takahari Daisuke,Suzuki Wataru,Yokokawa Takashi^ORCID,Minowa Yuichi,Hiraoka Tomoko,Suzuki Kenichi,Sato Hitoshi,Hama Toshihiro,Yamaguchi Kensei

Funder

Japan Research Foundation for Clinical Pharmacology

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology

Link

https://link.springer.com/content/pdf/10.1007/s00280-021-04237-x.pdf

Reference30 articles.

1. Wilhelm SM, Dumas J, Adnane L, Lynch M, Carter CA, Schütz G, Thierauch KH, Zopf D (2011) Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int J Cancer 129(1):245–255. https://doi.org/10.1002/ijc.25864

2. Grothey A, Van Cutsem E, Sobrero A, Siena S, Falcone A, Ychou M, Humblet Y, Bouché O, Mineur L, Barone C, Adenis A, Tabernero J, Yoshino T, Lenz HJ, Goldberg RM, Sargent DJ, Cihon F, Cupit L, Wagner A, Laurent D, Group CS (2013) Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 381(9863):303–312. https://doi.org/10.1016/S0140-6736(12)61900-X

3. Yoshino T, Komatsu Y, Yamada Y, Yamazaki K, Tsuji A, Ura T, Grothey A, Van Cutsem E, Wagner A, Cihon F, Hamada Y, Ohtsu A (2015) Randomized phase III trial of regorafenib in metastatic colorectal cancer: analysis of the CORRECT Japanese and non-Japanese subpopulations. Investig New Drugs 33(3):740–750. https://doi.org/10.1007/s10637-014-0154-x